Schroder is kicking off the second Isa season with the launch of a global
healthcare fund and a European technology fund.
The medical discovery fund, supported by cancer research, aims to
capitalise on companies creating new advances in the field of medicine and
takeover activity in pharmaceutical stocks.
Half of any retained initial charge together with a percentage of the
annual management charge will be paid to cancer research.
Stocks in the portfolio will include the likes of Astra Zeneca and Johnson
The EuroTech fund will invest primarily in European technology companies,
including the UK.
The initial charge on both funds is 5.25 per cent and the annual
management charge is 1.5 per cent. Commission is 3 per cent and renewal is
0.5 per cent.
The EuroTech fund is available as a Pep transfer.
Client services director Robin Stoakley says: “The medical discovery fund
is not a biotech fund but will encompass a broader spectrum of medical
“We did not want to launch a global tech fund because emphasis would have
focused on US stocks which are not as attractive as European stocks.”
Royal & Sun Alliance Investments has launched a pan-European technology
fund investing in about 50 stocks made up of both small and large-cap